<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19899">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01759511</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-322-0206</org_study_id>
    <nct_id>NCT01759511</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Study of GS-6624 to Treat Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in
      participants with Idiopathic Pulmonary Fibrosis (IPF) who had previously participated in
      Gilead clinical trial AB0024-201.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a measure for safety and tolerability</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>FVC is a pulmonary function test, and is defined as the volume of air that can forcibly be blown out after taking a full breath.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffusing Lung Capacity for Carbon Monoxide (DLCO)</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>DLCO is a measurement to determine the extent to which oxygen passes from the air sacs of the lungs into the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>All-cause mortality will be assessed as a percentage of participants who die from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum LOXL2 levels</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Simtuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive simtuzumab every 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simtuzumab</intervention_name>
    <description>Simtuzumab 125 mg/mL administered subcutaneously</description>
    <arm_group_label>Simtuzumab</arm_group_label>
    <other_name>GS-6624</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous participation in Phase 1 Gilead clinical trial

          -  Diagnosis of Idiopathic Pulmonary Fibrosis

          -  Females of childbearing potential and non-vasectomized males must agree to use highly
             effective methods of contraception

          -  Females must discontinue nursing

          -  Comply with study requirements

          -  Have adequate organ function

        Exclusion Criteria:

          -  History or evidence of clinically significant disorder, condition or disease that
             would pose a risk or interfere with the study

          -  Pregnant or lactating

          -  Clinically significant heart, hepatic or renal disease

          -  History of cancer within 5 years of screening

          -  Infection that is not controlled despite antibiotics or other treatment

          -  History of bleeding diathesis within the last 6 months of Day 1

          -  Known history of Human Immunodeficiency Virus, hepatitis B or C

          -  Concern's for subjects compliance

          -  Other conditions that might put the subject at high risk for treatment complications
             or reduce the chance to obtain data required

          -  Placed on a lung transplant list

          -  Previous participation in an Idiopathic Pulmonary Fibrosis clinical trial other than
             for Gilead Sciences -6624
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O'Riordan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, Ltd.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>IPF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
